Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b double-blind, randomized, low-dose comparator-controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to incurable cancer diagnosis

Next Previous
Search
Trial Profile

A Phase 2b double-blind, randomized, low-dose comparator-controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to incurable cancer diagnosis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Psilocybin (Primary)
  • Indications Adjustment disorders
  • Focus Therapeutic Use
  • Sponsors Psyence Group

    • Most Recent Events

    • 17 Dec 2024 According to a Psyence Biomed media release, till date two trial sites in Australia - Vitalis and EMPAX - have been activated, and patient screening has commenced. company is also evaluating additional sites to potentially participate in the trial.
    • 17 Dec 2024 According to a Psyence Biomed media release, company announced Patient screening underway A leading clinical trial site management organization, Australian Clinical Trial Network has been engaged to implement patient recruitment and retention strategies and first patient expected to be randomized into the study in January.
    • 03 Dec 2024 According to a Psyence Biomed media release, first patient to be randomized in this trial imminently

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top